Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
5(71.4%)
Phase 1
2(28.6%)
7Total
Phase 2(5)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT03822455Phase 2Terminated

A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients with Cystic Fibrosis

Role: lead

NCT03698448Phase 2Withdrawn

A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis

Role: lead

NCT02157922Phase 2Completed

A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis

Role: lead

NCT02453789Phase 2Completed

A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection

Role: lead

NCT00970346Phase 1Completed

Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis

Role: lead

NCT01991028Phase 2Completed

A Study to Investigate Lung Deposition of Radiolabelled OligoG

Role: collaborator

NCT01465529Phase 1Completed

A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. Fibrosis

Role: lead

All 7 trials loaded